Achieve Life Sciences, Inc. (NASDAQ:ACHV) Shares Acquired by Renaissance Technologies LLC

Renaissance Technologies LLC boosted its holdings in Achieve Life Sciences, Inc. (NASDAQ:ACHV) by 134.2% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 25,060 shares of the biopharmaceutical company’s stock after buying an additional 14,360 shares during the quarter. Renaissance Technologies LLC’s holdings in Achieve Life Sciences were worth $118,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of ACHV. CVI Holdings LLC bought a new stake in shares of Achieve Life Sciences during the 1st quarter worth $2,578,000. Vanguard Group Inc. lifted its stake in Achieve Life Sciences by 56.6% in the 1st quarter. Vanguard Group Inc. now owns 948,441 shares of the biopharmaceutical company’s stock worth $4,311,000 after acquiring an additional 342,731 shares in the last quarter. Propel Bio Management LLC acquired a new stake in Achieve Life Sciences during the 1st quarter worth about $11,149,000. Virtu Financial LLC purchased a new position in Achieve Life Sciences during the 1st quarter valued at about $59,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Achieve Life Sciences in the 2nd quarter valued at about $482,000. Institutional investors own 33.52% of the company’s stock.

Analyst Ratings Changes

A number of brokerages recently commented on ACHV. Raymond James assumed coverage on shares of Achieve Life Sciences in a research report on Friday, September 27th. They set a “strong-buy” rating and a $20.00 price objective on the stock. Oppenheimer restated an “outperform” rating and set a $11.00 price target on shares of Achieve Life Sciences in a report on Thursday, August 15th.

Achieve Life Sciences Price Performance

Shares of Achieve Life Sciences stock opened at $5.00 on Monday. The firm has a fifty day moving average price of $4.54 and a two-hundred day moving average price of $4.71. The company has a market cap of $171.70 million, a PE ratio of -4.50 and a beta of 1.56. The company has a debt-to-equity ratio of 0.21, a current ratio of 4.56 and a quick ratio of 4.56. Achieve Life Sciences, Inc. has a fifty-two week low of $3.03 and a fifty-two week high of $5.98.

Achieve Life Sciences (NASDAQ:ACHV) last announced its quarterly earnings results on Tuesday, August 13th. The biopharmaceutical company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by ($0.03). During the same quarter in the previous year, the company earned ($0.43) EPS. Analysts expect that Achieve Life Sciences, Inc. will post -1.03 EPS for the current year.

Achieve Life Sciences Company Profile

Achieve Life Sciences, Inc, a clinical-stage pharmaceutical company, develops and commercializes cytisinicline for smoking cessation and nicotine addiction. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms.